Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases

被引:28
作者
Gazzinelli, RT [1 ]
机构
[1] FDN OSWALDO CRUZ, CTR PESQUISAS RENE RACHOU, LAB CHAGAS DIS, BR-30190002 BELO HORIZONTE, MG, BRAZIL
来源
MOLECULAR MEDICINE TODAY | 1996年 / 2卷 / 06期
关键词
D O I
10.1016/1357-4310(96)88807-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A major goal for immunologists dealing with infectious diseases is the development of vaccines and immunotherapies that will protect patients against infection or the undesired effects of immune responses elicited by pathogens, Studies defining the function of different cytokines have contributed to the progress of new strategies to manipulate the immune response, Recent studies have demonstrated that interleukin 12 (lL-12) is a key cytokine for promoting cell-mediated immunity and initiating resistance to infection, Because IL-12 Is a potent stimulator of host defense against a variety of pathogens, it holds great promise for therapeutic use, in addition, IL-12 antagonists protect the host against immunopathology and death caused by an excessive cellular immune response that can occur during acute microbial infections.
引用
收藏
页码:258 / 267
页数:10
相关论文
共 41 条
[1]   THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR [J].
AFONSO, LCC ;
SCHARTON, TM ;
VIEIRA, LQ ;
WYSOCKA, M ;
TRINCHIERI, G ;
SCOTT, P .
SCIENCE, 1994, 263 (5144) :235-237
[2]  
ALIBERTI JCS, 1995, MEM I OSWALDO CRU S1, V90, P172
[3]  
BI ZB, 1995, J IMMUNOL, V155, P5684
[4]   EFFECTS OF IL-12 ON IMMUNE-RESPONSES TO MICROBIAL INFECTIONS - A KEY MEDIATOR IN REGULATING DISEASE OUTCOME [J].
BIRON, CA ;
GAZZINELLI, RT .
CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (04) :485-496
[5]  
Bohn E, 1996, J IMMUNOL, V156, P1458
[6]   Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice [J].
Carrera, L ;
Gazzinelli, RT ;
Badolato, R ;
Hieny, S ;
Muller, W ;
Kuhn, R ;
Sacks, DL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :515-526
[7]   IMPAIRED INTERLEUKIN-12 PRODUCTION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS [J].
CHEHIMI, J ;
STARR, SE ;
FRANK, I ;
DANDREA, A ;
MA, XJ ;
MACGREGOR, RR ;
SENNELIER, J ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (04) :1361-1366
[8]   CYTOKINE TREATMENT OF CENTRAL-NERVOUS-SYSTEM INFECTION - EFFICACY OF INTERLEUKIN-12 ALONE AND SYNERGY WITH CONVENTIONAL ANTIFUNGAL THERAPY IN EXPERIMENTAL CRYPTOCOCCOSIS [J].
CLEMONS, KV ;
BRUMMER, E ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :460-464
[9]   RESTORATION OF HIV-SPECIFIC CELL-MEDIATED IMMUNE-RESPONSES BY INTERLEUKIN-12 IN-VITRO [J].
CLERICI, M ;
LUCEY, DR ;
BERZOFSKY, JA ;
PINTO, LA ;
WYNN, TA ;
BLATT, SP ;
DOLAN, MJ ;
HENDRIX, CW ;
WOLF, SF ;
SHEARER, GM .
SCIENCE, 1993, 262 (5140) :1721-1724
[10]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398